Back to top

oncology-screening: Archive

Kevin Cook

Bull of the Day: NeoGenomics (NEO)

Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite

NEOPositive Net Change NTRAPositive Net Change GHNegative Net Change

Zacks Equity Research

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change IPHAPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

BMYPositive Net Change MRTXPositive Net Change